Gefitinib Patent Expiration
Gefitinib is Used for treating patients with metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. It was first introduced by Astrazeneca Uk Ltd
Gefitinib Patents
Given below is the list of patents protecting Gefitinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Iressa | US5770599 | Quinazoline derivatives |
May 05, 2017
(Expired) | Astrazeneca |
| Iressa | US5770599 | Quinazoline derivatives |
May 05, 2017
(Expired) | Astrazeneca |
| Iressa | US5457105 | Quinazoline derivatives useful for treatment of neoplastic disease |
Jan 19, 2013
(Expired) | Astrazeneca |
| Iressa | US5616582 | Quinazoline derivatives as anti-proliferative agents |
Jan 19, 2013
(Expired) | Astrazeneca |
Gefitinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Gefitinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
